REGENXBIO Statistics

Total Valuation

REGENXBIO has a market cap or net worth of $448.55 million. The enterprise value is $468.22 million.

Market Cap	448.55M
Enterprise Value	468.22M

Important Dates

The next estimated earnings date is Tuesday, May 5, 2026, after market close.

Earnings Date	May 5, 2026
Ex-Dividend Date	n/a

Share Statistics

REGENXBIO has 51.62 million shares outstanding. The number of shares has increased by 4.17% in one year.

Current Share Class	51.62M
Shares Outstanding	51.62M
Shares Change (YoY)	+4.17%
Shares Change (QoQ)	+0.12%
Owned by Insiders (%)	8.23%
Owned by Institutions (%)	71.03%
Float	43.00M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.63
Forward PS	1.78
PB Ratio	4.30
P/TBV Ratio	4.37
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	2.75
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.38, with a Debt / Equity ratio of 2.54.

Current Ratio	2.38
Quick Ratio	2.27
Debt / Equity	2.54
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-3.58

Financial Efficiency

Return on equity (ROE) is -107.00% and return on invested capital (ROIC) is -111.72%.

Return on Equity (ROE)	-107.00%
Return on Assets (ROA)	-21.93%
Return on Invested Capital (ROIC)	-111.72%
Return on Capital Employed (ROCE)	-48.13%
Weighted Average Cost of Capital (WACC)	11.65%
Revenue Per Employee	$459,410
Profits Per Employee	-$522,582
Employee Count	371
Asset Turnover	0.37
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -5.03% in the last 52 weeks. The beta is 1.13, so REGENXBIO's price volatility has been higher than the market average.

Beta (5Y)	1.13
52-Week Price Change	-5.03%
50-Day Moving Average	8.72
200-Day Moving Average	10.53
Relative Strength Index (RSI)	46.11
Average Volume (20 Days)	555,892

Short Selling Information

The latest short interest is 6.94 million, so 13.45% of the outstanding shares have been sold short.

Short Interest	6.94M
Short Previous Month	6.71M
Short % of Shares Out	13.45%
Short % of Float	16.15%
Short Ratio (days to cover)	9.75

Income Statement

In the last 12 months, REGENXBIO had revenue of $170.44 million and -$193.88 million in losses. Loss per share was -$3.76.

Revenue	170.44M
Gross Profit	-78.16M
Operating Income	-161.20M
Pretax Income	-193.88M
Net Income	-193.88M
EBITDA	-145.58M
EBIT	-161.20M
Loss Per Share	-$3.76

Full Income Statement

Balance Sheet

The company has $230.07 million in cash and $260.52 million in debt, giving a net cash position of -$19.66 million or -$0.38 per share.

Cash & Cash Equivalents	230.07M
Total Debt	260.52M
Net Cash	-19.66M
Net Cash Per Share	-$0.38
Equity (Book Value)	102.73M
Book Value Per Share	2.02
Working Capital	163.19M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$123.96 million and capital expenditures -$2.41 million, giving a free cash flow of -$126.38 million.

Operating Cash Flow	-123.96M
Capital Expenditures	-2.41M
Depreciation & Amortization	15.62M
Net Borrowing	n/a
Free Cash Flow	-126.38M
FCF Per Share	-$2.45

Full Cash Flow Statement

Margins

Gross margin is -45.86%, with operating and profit margins of -94.58% and -113.75%.

Gross Margin	-45.86%
Operating Margin	-94.58%
Pretax Margin	-113.75%
Profit Margin	-113.75%
EBITDA Margin	-85.42%
EBIT Margin	-94.58%
FCF Margin	n/a

Dividends & Yields

REGENXBIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.17%
Shareholder Yield	-4.17%
Earnings Yield	-43.22%
FCF Yield	-28.17%

Analyst Forecast

The average price target for REGENXBIO is $28.75, which is 230.84% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$28.75
Price Target Difference	230.84%
Analyst Consensus	Strong Buy
Analyst Count	8
Revenue Growth Forecast (5Y)	27.93%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

REGENXBIO has an Altman Z-Score of -3.04 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.04
Piotroski F-Score	3